Grace C. Limandjaja

Grace C. Limandjaja

Auto-generated profile, based on publicly available information

Grace C. Limandjaja

Department of Molecular Cell Biology and Immunology, Amsterdam University Medical Centre (location VUmc), Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Experimental Dermatology
Verified
Journal Article
Open access
PDF file
GLGrace C. Limandjaja
Grace C. Limandjaja
FNFrank B. Niessen
Frank B. Niessen
RSRik J. Scheper
Rik J. Scheper
SGSue Gibbs
Sue Gibbs
Although hypertrophic scars and keloids both generate excessive scar tissue, keloids are characterized by their extensive growth beyond the borders of the original wound, which is not observed in hypertrophic scars. Whether or not hypertrophic scars and keloids are two sides of the same coin or in fact distinct entities remains a topic of much debate. However, proper comparison between the two ideally occurs within the same study, but this is the exception rather than the rule. For this reason, the goal of this review was to summarize and evaluate all publications in which both hypertrophic scars and keloids were studied and compared to one another within the same study. The presence of horizontal growth is the mainstay of the keloid diagnosis and remains the strongest argument in support of keloids and hypertrophic scars being distinct entities, and the histopathological distinction is less straightforward. Keloidal collagen remains the strongest keloid parameter, but dermal nodules and α‐SMA immunoreactivity are not limited to hypertrophic scars alone. Ultimately, the current hypertrophic scars‐keloid differences are mostly quantitative in nature rather than qualitative, and many similar abnormalities exist in both lesions. Nonetheless, the presence of similarities does not equate the absence of fundamental differences, some of which may not yet have been uncovered given how much we still have to learn about the processes involved in normal wound healing. It therefore seems pertinent to continue treating hypertrophic scars and keloids as separate entities, until such a time as new findings more decisively convinces us otherwise.

28 May 2014 in Experimental Dermatology
Verified
Journal Article
Open access
PDF file
LBLenie J. van Den Broek
Lenie J. van Den Broek
GLGrace C. Limandjaja
Grace C. Limandjaja
FNFrank B. Niessen
Frank B. Niessen
SGSue Gibbs
Sue Gibbs
Most cutaneous wounds heal with scar formation. Ideally, an inconspicuous normotrophic scar is formed, but an abnormal scar (hypertrophic scar or keloid) can also develop. A major challenge to scientists and physicians is to prevent adverse scar formation after severe trauma (e.g. burn injury) and understand why some individuals will form adverse scars even after relatively minor injury. Currently, many different models exist to study scar formation, ranging from simple monolayer cell culture to 3D tissue‐engineered models even to humanized mouse models. Currently, these high‐/medium‐throughput test models avoid the main questions referring to why an adverse scar forms instead of a normotrophic scar and what causes a hypertrophic scar to form rather than a keloid scar and also, how is the genetic predisposition of the individual and the immune system involved. This information is essential if we are to identify new drug targets and develop optimal strategies in the future to prevent adverse scar formation. This viewpoint review summarizes the progress on in vitro and animal scar models, stresses the limitations in the current models and identifies the future challenges if scar‐free healing is to be achieved in the future.

1 January 2009 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
GLG.C. Limandjaja
G.C. Limandjaja
CBC.C. Breugem
C.C. Breugem
AMA.B. Mink van der Molen
A.B. Mink van der Molen
MKM. Kon
M. Kon

26 November 2016 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
GLG. C. Limandjaja
G. C. Limandjaja
LBL. J. van Den Broek
L. J. van Den Broek
TWT. Waaijman
T. Waaijman
HVH.A. Veen
H.A. Veen
VEV. Everts
V. Everts
SGSue Gibbs
Sue Gibbs
The pathogenesis underlying keloid formation is still poorly understood. Research has focused mostly on dermal abnormalities, while the epidermis has not yet been studied. To identify differences within the epidermis of mature keloid scars compared with normal skin and mature normotrophic and hypertrophic scars. Rete ridge formation and epidermal thickness were evaluated in tissue sections. Epidermal proliferation was assessed using immunohistochemistry (Ki67, keratins 6, 16 and 17) and with an in vitro proliferation assay. Epidermal differentiation was evaluated using immunohistochemistry (keratin 10, involucrin, loricrin, filaggrin, SPRR2, SKALP), reverse-transcriptase polymerase chain reaction (involucrin) and transmission electron microscopy (stratum corneum). All scars showed flattening of the epidermis. A trend of increasing epidermal thickness correlating to increasing scar abnormality was observed when comparing normal skin, normotrophic scars, hypertrophic scars and keloids. No difference in epidermal proliferation was observed. Only the early differentiation marker involucrin showed abnormal expression in scars. Involucrin was restricted to the granular layer in healthy skin, but showed panepidermal expression in keloids. Normotrophic scars expressed involucrin in the granular and upper spinous layers, while hypertrophic scars resembled normotrophic scars or keloids. Abnormal differentiation was associated with ultrastructural disorganization of the stratum corneum in keloids compared with normal skin. Keloids showed increased epidermal thickness compared with normal skin and normotrophic and hypertrophic scars. This was not due to hyperproliferation, but possibly caused by abnormal early terminal differentiation, which affects stratum corneum formation. Our findings indicate that the epidermis is associated with keloid pathogenesis and identify involucrin as a potential diagnostic marker for abnormal scarring.

17 June 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
GLG.C. Limandjaja
G.C. Limandjaja
JBJ.M. Belien
J.M. Belien
RSR.J. Scheper
R.J. Scheper
FNF.B. Niessen
F.B. Niessen
SGSue Gibbs
Sue Gibbs
Background Our understanding of the pathogenesis underlying keloid scar formation is still very limited, and the morphological distinction between hypertrophic and keloid scars remains difficult. Objectives Using whole biopsy imaging and an objectively quantifiable way to analyze immunoreactivity, we have compared young immature scars (Yscar) with mature normal (Nscar) scars, hypertrophic (Hscar) scars, and keloid (Kscar) scars with their surrounding skin (sNskin). Results Abnormal scars (Hscar and Kscar) maintain the Yscar phenotype, characterized by a CD34− (tumour biomarker) / α‐SMA+ (myofibroblast) dermal region in contrast to Nskin (normal skin), sNskin and mature Nscar which were CD34+/α‐SMA−. Yscar, Kscar and Hscar showed abnormal epidermal differentiation (involucrin), but only Hscar and Kscar showed increased epidermal thickness. Yscar did show increased epidermal and dermal proliferation (Ki67), which was absent from abnormal scars where mesenchymal hypercellularity (vimentin) and senescence (p16) were predominant. Keloidal collagen and α‐SMA were previously considered to distinguish between Hscar and Kscar. However, α‐SMA staining was present in both abnormal scars, while keloidal collagen was mostly present in Kscar. There were no obvious signs of heterogeneity within keloid scars, and sNskin resembled Nskin. Conclusions Both abnormal scar types (Hscar and Kscar) showed a unique CD34−/α‐SMA+/p16+ scar phenotype, but the differences between Hscar and Kscar observed in this study were of a gradient rather than absolute nature. This suggests that scar progression to the mature normal scar phenotype is, for as yet unknown reasons, hindered in hypertrophic and keloid scars.

1 April 2018 in Tissue Engineering Part C: Methods
Verified
Journal Article
Closed access
GLGrace C. Limandjaja
Grace C. Limandjaja
LBLenie J. van Den Broek
Lenie J. van Den Broek
MBMelanie Breetveld
Melanie Breetveld
TWTaco Waaijman
Taco Waaijman
SMStan Monstrey
Stan Monstrey
SGSue Gibbs
Sue Gibbs
To understand scar pathology, develop new drugs, and provide a platform for personalized medicine, physiologically relevant human scar models are required which are characteristic of different scar pathologies. Hypertrophic scars and keloids are two types of abnormal scar resulting from unknown abnormalities in the wound healing process. While they display different clinical behavior, differentiation between the two can be difficult - which in turn means that it is difficult to develop optimal therapeutic strategies. The aim of this study was to develop in vitro reconstructed human hypertrophic and keloid scar models and compare these to normotrophic scar and normal skin models to identify distinguishing biomarkers. Keratinocytes and fibroblasts from normal skin and scar types (normotrophic, hypertrophic, keloid) were used to reconstruct skin models. All skin models showed a reconstructed differentiated epidermis on a fibroblast populated collagen-elastin matrix. Both abnormal scar types showed increased contraction, dermal thickness and myofibroblast staining compared to normal skin and normotrophic scar. Notably, the expression of extracellular matrix associated genes showed distinguishing profiles between all scar types and normal skin (hyaluronan synthase-1, matrix-metalloprotease-3), between keloid and normal skin (collagen type IV), between normal scar and keloid (laminin α1) and between keloid and hypertrophic scar (matrix-metalloprotease-1, integrin α5). Also, inflammatory cytokine and growth factor secretion (CCL5, CXCL1, CXCL8, CCL27, IL-6, HGF) showed differential secretion between scar types. Our results strongly suggest that abnormal scars arise from different pathologies rather than simply being on different ends of the scarring spectrum. Furthermore, such normal skin and scar models together with biomarkers which distinguish the different scar types would provide an animal free, physiologically relevant scar diagnostic and drug testing platform for the future.